CG
MACK

Cutler Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Cutler Group’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-636
Closed -$1K – 7333
2017
Q2 		$1K Sell
636
-317
-33% -$6.47K ﹤0.01% 6215
2017
Q1 		$1K Buy
+953
New +$23.8K ﹤0.01% 6217
2016
Q3 		– Sell
-127
Closed -$2K – 7844
2016
Q2 		$2K Sell
127
-242
-66% -$13.2K ﹤0.01% 5892
2016
Q1 		$1K Sell
369
-902
-71% -$47.1K ﹤0.01% 6312
2015
Q4 		$12K Buy
+1,271
New +$89.4K ﹤0.01% 3995

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cutler Group's MACK Position: Q4 2017 in Review

Cutler Group sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2017, closing a stake of 674 shares — an estimated $7K sold.

Cutler Group first reported a position in MACK in Q4 2015 and held it in 5 quarters. The position peaked at $46K in Q1 2017. 78 funds tracked by Wall St. Rank hold MACK as of Q4 2017.

  • Cutler Group reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Cutler Group sold 674 Merrimack Pharmaceuticals, Inc. shares in Q4 2017, an estimated $7K.
  • Cutler Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2015 and held it in 5 quarters.
  • Cutler Group's Merrimack Pharmaceuticals, Inc. position peaked at $46K in Q1 2017.
  • 78 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2017.

Based on Cutler Group's 13F filing for Q4 2017, filed 17 Jan 2018.